Subject: The Medication Affordability and Patent Integrity Act (S.2658)

From	CSRxP <[email protected]>
Subject	The Medication Affordability and Patent Integrity Act (S.2658)
Date	June 11, 2026 7:15 PM

Links have been removed from this email. Learn more in the FAQ.

Brand name drug manufacturers game the patent system and drug approval process
by presenting one narrative to the U.S. Food & Drug Administration (FDA) and
another to the U.S. Patent and Trademark Office (USPTO).

Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx

This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>

Screenshot of the email generated on import

Message Analysis

Sender: n/a
Political Party: n/a
Country: n/a
State/Locality: n/a
Office: n/a
Email Providers:
- Iterable